Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has been identified as one of the most oversold penny stocks to buy. Health Canada has conditionally approved Amtagvi, a tumor-derived T cell immunotherapy for adult patients with unresectable or metastatic melanoma, marking a significant milestone for the company.

The approval is contingent on further clinical trials validating its efficacy. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) specializes in developing and providing tumor-infiltrating lymphocyte therapies for solid tumor cancers.

While IOVA shows promise as an investment, some believe that certain AI stocks offer greater potential for growth and lower downside risk. For further insights, consider exploring the best short-term AI stocks in a free report.

Read more at Yahoo Finance: Iovance Biotherapeutics (IOVA) Receives Conditional Approval From Health Canada